Once‐weekly semaglutide use in patients with type 2 diabetes: Results from the SURE France multicentre, prospective, observational study

Abstract

AbstractAimsReal‐world data are required to support glucagon‐like peptide‐1 receptor agonist use in type 2 diabetes (T2D). SURE France assessed once‐weekly semaglutide in adults with T2D in real‐world clinical practice.Materials and MethodsThis multicentre, prospective, open‐label, single‐arm study included adults with T2D and ≥1 documented glycated haemoglobin (HbA1c) value ≤12 weeks before semaglutide initiation. The primary endpoint was HbA1c change from baseline to end of study (EOS; ~30 weeks). Secondary endpoints included change from baseline to EOS in body weight (BW) and waist circumference (WC); and proportion achieving HbA1c targets. Baseline characteristics and safety were reported for the full analysis set (patients initiating semaglutide). Analysis of other endpoints was based on the effectiveness analysis set (study completers receiving semaglutide at EOS).ResultsOf 497 patients initiating semaglutide (41.6% female, mean age 58.3 years), 348 completed the study on treatment. Baseline HbA1c, diabetes duration, BW and WC, were 8.3%, 10.0 years, 98.2 kg and 114.2 cm, respectively. The most common reasons for initiating semaglutide were to improve glycaemic control (79.7%), reduce BW (69.8%) and address cardiovascular risk (24.1%). At EOS, mean changes were: HbA1c, –1.2% points [95% confidence interval (CI) –1.32; –1.10]; BW, –4.7 kg (95% CI –5.38; –4.07); and WC, –4.9 cm (95% CI –5.94; –3.88). At EOS, 81.7%, 67.7% and 51.6% of patients achieved an HbA1c target of <8.0%, <7.5% and <7.0%, respectively. No new safety concerns were identified.ConclusionsThese results support the benefits of semaglutide in a real‐world setting in adults with T2D in France showing a significant reduction in HbA1c and body weight.